Deutsche Bank’s Autolus Therapeutics AUTL Stock Holding History

Deutsche Bank’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,876	Closed	-$99K	–	4399
2021 Q2	$99K	Buy	+14,876	New	+$92.3K	﹤0.01%	4150
2019 Q3	–	Sell	-12,221	Closed	-$196K	–	4871
2019 Q2	$196K	Buy	12,221 +12,129	+13,184%	+$271K	﹤0.01%	3838
2019 Q1	$2K	Buy	+92	New	+$2.62K	﹤0.01%	5072

Other funds holding AUTL

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Deutsche Bank's AUTL Position: Q3 2021 in Review

Deutsche Bank sold out of Autolus Therapeutics (AUTL) in Q3 2021, closing a stake of 14,876 shares — an estimated $99K sold.

Deutsche Bank first reported a position in AUTL in Q1 2019 and held it in 3 quarters. The position peaked at $196K in Q2 2019. 59 funds tracked by Wall St. Rank hold AUTL as of Q3 2021.

Deutsche Bank reported no remaining Autolus Therapeutics position as of Q3 2021 after selling out during the quarter.
Deutsche Bank sold 14,876 Autolus Therapeutics shares in Q3 2021, an estimated $99K.
Deutsche Bank first reported a position in Autolus Therapeutics in Q1 2019 and held it in 3 quarters.
Deutsche Bank's Autolus Therapeutics position peaked at $196K in Q2 2019.
59 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2021.

Based on Deutsche Bank's 13F filing for Q3 2021, filed 4 Nov 2021.